What “Buy and Bill” Means for an IBD Infusion

If you receive infliximab or vedolizumab by IV, someone had to purchase that vial before a nurse could hang it. In most cases that someone is the clinic or hospital where you get treated. The arrangement is called buy and bill, and it explains why your infusion usually appears on your insurance statements as a medical service rather than a prescription. Knowing who buys the drug, who bills your plan for it, and where the infusion happens accounts for most of the surprises inflammatory bowel disease patients hit with infusion costs, prior authorization, and sudden requests to change treatment locations.

What Buy and Bill Actually Means

Buy and bill is the traditional acquisition model for provider-administered drugs. The infusion provider purchases the drug from a wholesaler, holds it in inventory, administers it to you, and then bills your health plan for both the drug and the administration. An analysis of these arrangements describes providers who "buy drugs directly from drug wholesalers and then bill payers for the drug at a higher price," with hospital markups reaching 200 to 300 percent of the base price of the drug, intended to cover the operational and infrastructure costs of storing and managing specialty drugs.

The size of that markup depends on the payer. Medicare sets payment for separately billable drugs at 106 percent of the average sales price. Commercial plans negotiate their own rates with each hospital and practice, which is why the identical vial can carry very different prices across two buildings in the same city. For you, the practical result is one medical claim covering both the drug and the chair time, submitted by the site that treated you.

Why Infused Biologics Sit on the Medical Benefit

Infused biologics used in IBD are drugs you cannot give yourself. The Remicade label states that the drug is "administered by intravenous infusion for at least 2 hours with an in-line filter", with maintenance dosing of 5 mg/kg every 8 weeks. The American College of Gastroenterology describes biologics for ulcerative colitis as medications given by IV or a shot. Medicare Part B covers drugs and biologicals that are "not usually self-administered" when they are furnished incident to a physician's service, and commercial plans follow similar logic. Roughly half of specialty pharmaceuticals are covered under the medical benefit and half under the pharmacy benefit.

Which benefit applies changes the rules you face. A review of 1,619 paired medical and pharmacy coverage policies at major commercial plans found 14 percent were discordant, most often because of step therapy requirements. The same drug can carry different prerequisites depending on the pathway. Some products now exist in both forms. Entyvio is labeled for 300 mg intravenous induction with either IV maintenance every eight weeks or 108 mg subcutaneously every two weeks, so a change in route can move you from one benefit to the other.

White Bagging and Brown Bagging

Payers have built alternatives to buy and bill. Under white bagging, a payer-affiliated specialty pharmacy supplies the drug and the clinician is reimbursed only for drug administration, without any markup on the cost of the drug itself. The pharmacy ships the product directly to the site of care just in time for the patient's scheduled treatment. Under brown bagging, the payer's specialty pharmacy delivers the drug to you, and you either bring it to the appointment or use it at home through a home infusion program. A third variation, clear bagging, has a hospital fill the prescription through its own specialty pharmacy and move it internally to the infusion suite.

These models change practical details of your care. The vial is labeled for you specifically, so a weight-based dose adjustment or a rescheduled appointment can strand product that cannot be given to anyone else. Billing may shift from the medical benefit to the pharmacy benefit, which can turn a percentage-based coinsurance charge into a flat copay, or the reverse.

Why Your Infusion Location Keeps Changing

Site of service policies require patients to receive treatment at a lower-cost setting, either a clinician's office outside a hospital-based system, a stand-alone infusion center, or home. The driver is price. A matched cohort analysis of 52,760 infusions among 18,988 commercially insured patients across seven chronic conditions, including Crohn's disease and ulcerative colitis, found infusion claim costs 41.8 percent higher in hospital outpatient departments, a difference of about $4,356 per infusion, with no significant differences in emergency department visits, inpatient admissions, adverse events, or 12-month adherence.

Because medical benefit cost sharing is usually a percentage of the allowed amount, a higher-priced site generally means a larger patient share until you reach your deductible and out-of-pocket limit. Plans have also worked the other direction by paying practices to keep patients out of hospitals. One Ohio health plan supplied infliximab through its specialty pharmacy and added an infusion case rate to compensate gastroenterology practices for nursing time and supplies, and all three participating practices continued office-based infusions.

Billing Questions Worth Asking

Cost and paperwork both affect whether treatment actually happens. A systematic review found specialty drug abandonment rates of 1.3 to 10 percent when cost sharing was $0 to $50, rising to 32 to 75 percent when cost sharing exceeded $100, with prior authorization adding delays of 3.6 to 31 days. In pediatric IBD specifically, prior authorization extended biologic start times by about 10 days for uncomplicated cases and 25 days when appeals or step therapy were involved, and those delays came with a 12.9 percent increase in the likelihood of hospitalization, emergency care, or surgery within six months.

Three questions cover most of the ground before an infusion is scheduled or moved:

• Who buys this drug, and will it be billed under my medical benefit or my pharmacy benefit?
• What is the plan's allowed amount at this specific site, and what is my estimated share once the deductible is applied?
• If the plan requires white bagging, what happens to the shipped vial if my dose changes or I miss the appointment?

Write down the answers along with the date and the name of the person who gave them. Acquisition models, benefit assignments, and site-of-care rules are all renegotiated at the plan level, often at the start of a plan year, and the version of the answer you were given in January may not be the version in force in July. A written record of who said what is the fastest way to challenge a bill that does not match what you were told.